Novartis AG Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated July 15, 2010, reports the financial results for Novartis AG for the second quarter and first half of 2010. The Swiss-based pharmaceutical company reported strong double-digit growth driven by portfolio rejuvenation, innovation, and productivity initiatives. The reporting period covers operations across Pharmaceuticals, Vaccines and Diagnostics, Sandoz (generics), and Consumer Health divisions.
Key Financial Metrics
| Metric | Q2 2010 | Q2 2009 | H1 2010 | H1 2009 |
|---|---|---|---|---|
| Net Sales (USD) | 11.7 billion | 10.5 billion | 23.8 billion | 20.3 billion |
| Operating Income (USD) | 3.0 billion | 2.4 billion | 6.5 billion | 4.7 billion |
| Net Income (USD) | 2.4 billion | 2.0 billion | 5.4 billion | 4.0 billion |
| Earnings Per Share (USD) | 1.06 | 0.90 | 2.34 | 1.76 |
| Free Cash Flow (USD) | 2.4 billion | 1.9 billion | 5.3 billion | 3.4 billion |
| Core Operating Margin | 28.0% | 25.3% | 29.9% | 26.0% |
| Financial Debt (USD) | 18.6 billion (as of June 30, 2010) | |||
| Net Liquidity (USD) | 4.4 billion (as of June 30, 2010) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 net sales rose 11% (12% in constant currencies), driven by a 12 percentage point volume increase. Recently launched products contributed 21% of total sales.
- Profitability: Operating income increased 25% in Q2. Core operating margin improved by 2.7 percentage points to 28.0%.
- Divisional Performance:
- Pharmaceuticals: Sales up 8% (cc), with strong growth in Oncology (+11%) and Cardiovascular (+8%).
- Vaccines & Diagnostics: Sales surged 135% (cc) in Q2, largely due to USD 200 million in A(H1N1) pandemic vaccine sales.
- Sandoz: Sales grew 13% (cc), driven by biosimilars (+66%) and the EBEWE Pharma acquisition.
- Consumer Health: Sales increased 7% (cc), outperforming markets in OTC and Animal Health.
- Exceptional Items: Q2 operating income included a USD 265 million pension gain, offset by USD 231 million in litigation provisions and USD 82 million in asset impairments.
Guidance, Outlook, and Risks
- 2010 Outlook: Novartis raised its full-year sales guidance to mid- to high-single-digit growth in constant currencies (excluding Alcon). Operating margins are expected to increase.
- Currency Impact: Exchange rates had a slightly negative impact (-1%) in Q2. A small negative impact is expected for the full year if rates remain current.
- Alcon Acquisition: The acquisition of a 77% majority stake in Alcon is expected to close in Q3 or Q4 2010. Financial modeling for Alcon is not yet included in the outlook.
- Innovation Pipeline:
- FDA Advisory Committee unanimously recommended approval for FTY720 (multiple sclerosis).
- US FDA approved Tasigna for first-line treatment of chronic myeloid leukemia.
- Afinitor missed the primary endpoint in the RADIANT 2 study for carcinoid tumors by a small statistical margin; data will be discussed with health authorities.
- Risks: Forward-looking statements are subject to risks including clinical trial results, regulatory delays, patent disputes, pricing pressures, and the global economic environment.
Investor Verification Checklist
- Verify the sustainability of A(H1N1) vaccine revenue contributions, as the campaign is largely complete.
- Monitor the timeline and regulatory outcome for the FTY720 (multiple sclerosis) approval.
- Assess the integration progress and financial impact of the EBEWE Pharma and Oriel Therapeutics acquisitions.
- Review the status of the Alcon acquisition closing and associated financing.
- Track the resolution of the RADIANT 2 study data for Afinitor and its potential impact on neuroendocrine tumor indications.
- Confirm the impact of currency fluctuations on the second-half outlook.